Soliris®| Eculizumab | Alexion
29 May 2020 | US | Alexion, Amgen | In a filing to the Securities and Exchange Commission, Alexion announces it has settled its eculizumab dispute with Amgen. Under the agreement, Amgen will receive a non-exclusive, royalty-free license to market its product from 01 March 2025.
10 Jan 2020 | CN | Samsung, AffaMed | Samsung and AffaMed announce Chinese approval for Phase III trials of eculizumab candidate.
09 Sep 2019 | EU | Alexion | Alexion reveals that the EPO denied two patent applications relating to its eculizumab product, as they await the full written response.
02 Sep 2019 | US | Amgen, Alexion | US Patent and Trial Board commences an inter partes review of Alexion's eculizumab patents following Amgen's claims that they were anticipated or obvious.
16 Aug 2019 | All | Samsung Bioepis | Samsung Bioepis commences patient enrolment for Phase III clinical study of eculizumab biosimilar candidate, SB12.
11 Apr 2019 | RU | Generium, Selexis | Selexis announces first biosimilar eculizumab approval in Russia through partnership with Generium.